Camurus appoints Behshad Sheldon as President of Camurus Inc.

Lund, Sweden — 13 February 2024 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Behshad Sheldon as President of Camurus Inc. and member of the company’s executive management team, starting 1 April 2024.

Behshad has been a member of Camurus’ Board of Directors since 2018, contributing to Camurus’ development as a successful and profitable, commercial-stage pharmaceutical company. Behshad brings more than 25 years of experience from leading positions within the international pharmaceutical industry, including as President & CEO of Braeburn Pharmaceuticals up to 2017, and from senior positions within Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals, where she led successful blockbuster brands such as Glucophage, Plavix, and Abilify. Most recently Behshad was a Managing Director at Biotech Value Advisors where she supported biotech and pharmaceutical companies with pre-launch and commercialization efforts in the US.

“We are delighted to welcome Behshad to Camurus to lead our US operations and planned product launches”, says Fredrik Tiberg, President and CEO of Camurus. “Behshad has an impressive track-record of successfully leading commercialization of several market-transforming drugs with billion-dollar sales in the US and globally, and we look forward to a great collaboration and building a strong business in the US.”

“I am thrilled to be joining Camurus at such an exciting, transformational time. I look forward to bringing my expertise in building commercial operations and blockbuster brands to the dynamic, agile, accountable, and inclusive culture that defines Camurus,” says Behshad Sheldon.

In December 2023 Camurus submitted a New Drug Application (NDA) to the US FDA for Oclaiz™ (CAM2029) for the treatment of acromegaly. An NDA acceptance to file and the Prescription Drug User Free Act date (also known as action date) is expected from the FDA shortly. In parallel, Camurus is building up an own commercial organization in the US to be ready for a planned launch of Oclaiz™ in the beginning of 2025.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About CamurusCamurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

The information was submitted for publication at 8:00 am CET on 13 February 2024.